SCHEMBL23977249

SCHEMBL23977249

Fc1ccc2c(c1)CCC/C2=N\S

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 9/20 0.40
CYP19A1 P11511 8/20 0.40
CYP11B1 P15538 7/20 0.40
MAPT P10636 4/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
SRD5A1 P18405 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KMT2A Q03164 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31552701 0.82 L3MBTL1 (0.53) CYP11B2CYP19A1CYP11B1MAPTCASP3
SCHEMBL22043642 0.82 L3MBTL1 (0.53) CYP11B2CYP19A1CYP11B1MAPTCASP3
SCHEMBL31127800 0.78 MAPT (0.45) MAPTCASP3SENP8SENP7SENP6
SCHEMBL31127751 0.78 MAPT (0.45) MAPTCASP3SENP8SENP7SENP6
SCHEMBL24781210 0.72 GPR3 (0.36) CYP11B2CYP19A1CYP11B1MAPTCASP3
SCHEMBL23977248 0.72 GPR3 (0.36) CYP11B2CYP19A1CYP11B1MAPTCASP3
SCHEMBL30062796 0.72 GPR3 (0.36) CYP11B2CYP19A1CYP11B1MAPTCASP3
SCHEMBL315877 0.72 MAOA (0.61) SRD5A1MAOAMAOBKMT2AMEN1
SCHEMBL23678473 0.70 CYP11B2 (0.41) CYP11B2CYP19A1CYP11B1SRD5A1
SCHEMBL354708 0.70 HTT (0.62) CYP11B2CYP19A1CYP11B1SRD5A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed